ГЕНЕТИКА
GENETICS

УДК 575:616.89:616-053.2 **DOI: 10.18413/2658-6533-2019-5-3-0-1**

Ivan Y. Iourov[1,2,3], Thomas Liehr[4], Svetlana G. Vorsanova[1,2], Luis Alberto Mendez-Rosado[5], Yuri B. Yurov[1,2]

The applicability of interphase chromosome-specific multicolor banding (ICS-MCB) for studying neurodevelopmental and neurodegenerative disorders[1]

[1]Mental Health Research Center,
34 Kashirskoe Rd., Moscow, 115522, Russia
[2]Academician Y.E. Veltishchev Research Clinical Institute of Pediatrics,
Pirogov Russian National University,
2 Taldomskaya St., Moscow, 125412, Russia
[3]Russian Medical Academy of Continuous Postgraduate Education,
2/1 bld. 1 Barrikadnaya St., Moscow, 125993, Russia
[4]Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics,
Friedrich-Schiller-Universität Jena, Jena, 07737, Germany
[5]National Center of Medical Genetics,
Calle 31 Esquina a 146 Nr. 3102 Reparto Cubanacán, 11600, Havana, La Habana, Cuba
Corresponding author: Ivan Y. Iourov (ivan.iourov@gmail.com)

Abstract

Background: Interphase chromosome-specific multicolor banding (ICS-MCB) has been developed for studying whole chromosomes in interphase nuclei at any stage of the cell cycle at molecular resolution. Previously, important biomedical discoveries have been made using the technique. In the postgenomic era, a need appears to exist for a reevaluation of molecular cytogenetic techniques, including ICS-MCB, which seems to take a well-deserved place. **Aim of the study**: The aim of the present study is to address the applicability of ICS-MCB for studying neurodevelopmental and neurodegenerative disorders. **Conclusions**: A brief overview of previous ICS-MCB applications demonstrates that the technique may provide an appreciable amount of unique data on chromosome abnormalities and organization in interphase nuclei. Furthermore, the technique offers opportunities for evaluating these phenomena in the diseased human brain. Such opportunity seems to be critical for unraveling molecular and cellular mechanisms of neurodevelopmental and neurodegenerative disorders. Therefore, we conclude that ICS-MCB may represent an important part of molecular and cellular studies of neurodevelopmental and neurodegenerative disorders.

Keywords: chromosome; chromosome instability; interphase nucleus; neurodegenerative disorders; neurodevelopmental disorders

[1] This article has been partially communicated at the congress dedicated to the memory of Prof. Yuri Yurov (Medical genomics: multidisciplinary aspects) held in St. Petersburg (26-29 March 2019).

Acknowledgements: Ivan I. Iourov, Svetlana G. Vorsanova and Luis Alberto Mendez-Rosado are supported by RFBR and CITMA according to the research project №18–515-34005.

For citation: Iourov IY, Liehr T, Vorsanova SG, et al. The applicability of interphase chromosome-specific multicolor banding (ICS-MCB) for studying neurodevelopmental and neurodegenerative disorders. Research Results in Biomedicine. 2019;5(3):4-9. DOI: 10.18413/2658-6533-2019-5-3-0-1

Introduction. Neurodevelopmental and neurodegenerative disorders have been systematically associated with genomic variations (i.e. chromosome abnormalities, copy number variations and single-gene mutations) [1-4]. Besides, genomic variations are commonly mosaic. Furthermore, somatic mosaicism is likely to be an important genetic mechanism for brain diseases. The most common types of somatic genomic variations are chromosomal mosaicism and instability [1, 3, 5-7]. However, despite these observations, somatic chromosomal mosaicism is still under observed. This is more likely because of unacceptable neglect to techniques available for studying intercellular genome variability [1, 7]. Fortunately, molecular cytogenetics does provide approaches towards studying genome variations at chromosomal level [8, 9]. Probably, the most important molecular cytogenetic technique for studying chromosomes in individual cells is interphase fluorescence in situ hybridization (FISH) [10]. The latter has been already shown to provide valuable data on chromosomal mosaicism and the contribution to brain pathology in neurodevelopmental and neurodegenerative disorders [7, 11, 12]. Currently, FISH still represents an important technology for studying chromosomal imbalances and chromosome organization in interphase nuclei regardless of the introduction of post-genomic technologies (i.e. next-generation sequencing and microarray-based methods) [10, 13-15]. The present communication pays attention to a FISH-based technique for studying individual interphase chromosomes in their integrity in single cells – interphase chromosome-specific multicolor banding (ICS-MCB) – and to the applicability for studying neurodevelopmental and neurodegenerative disorders.

ICS-MCB applications.ICS-MCB is a method combining interphase FISH and multicolor chromosomal banding (a FISH-based approach toward banding several chromosomal regions and subregions smaller than a chromosome arm through the use of microdissected DNA probes). The application of ICS-MCB on human cellular nuclei provides the depiction of homologous interphase chromosomes in their integrity at molecular resolution (see Iourov et al. [16, 17]). Actually, there is no true alternative to this technique for studying human interphase chromosomes in their integrity in individual cells [7, 10, 18]. Previously, ICS-MCB has been applied to identify chromosomal abnormalities and instability in the diseased human brain. Furthermore, the technique might be used for determining nuclear chromosome organization in almost all human tissues.

Somatic chromosomal mosaicism and chromosome instability has been repeatedly associated with neurodevelopmental and neurodegenerative disorders [1, 7, 19, 20]. More importantly, these types of genomic variability may be confined to the diseased brain. The phenomenon of brain-specific chromosomal mosaicism seems to play a significant role in the etiology of neurodevelopmental and neurodegenerative disorders [3, 7, 19, 21]. For instance, chromosomal instability, a process closely related to cancerization, has been uncovered to mediate neurodegeneration using ICS-MCB. Interphase chromosome breaks (ICB) have been found to be the commonest type of chromosomal instability mediating cerebellar neurodegeneration in ataxia-telangiectasia [22]. ICB are currently undetectable by any type of molecular (cytogenetic) techniques apart from ICS-MCB. Brain-specific aneuploidy and copy number variations have

been shown to be implicated in molecular and cellular pathways neurodegeneration [3, 19, 23]. Aneuploidy of chromosomes 21 and X uncovered by ICS-MCB has been found to be a common mechanism for Alzheimer's disease, one of the commonest neurodegenerative diseases in elderly persons [24-26]. Currently, such types of genomic variability are suggested to be key elements of the Alzheimer's disease pathogenetic cascade [27]. Age-specific chromosomal mosaicism requires to be addressed by high-resolution single-cell molecular cytogenetic techniques (i.e. ICS-MCB) [28, 29]. Finally, chromosomal instability (chromothripsis) appears to mediate brain dysfunction in neurodevelopmental and neurodegenerative disorders [30]. In total, the phenomena identified using ICS-MCB have been recognized as genomic mechanisms of intercellular genetic variation in health and disease [31, 32].

Alternatively, ICS-MCB may be applied for studying chromosome arrangement in interphase nuclei [3, 10, 16, 17, 21]. It is to note that positioning of chromosomes in the nucleus and its impact on transcriptional genome activity and genome stability maintenance have not been evaluated in the majority of human tissues. The application of ICS-MCB would be certainly valuable to fill this gap in our biomedical knowledge. It is highly likely that chromosome nuclear organization is specific for a variety of brain diseases including those leading to neurodevelopmental and neurodegenerative disorders.

Taking into account previous experience, one may define a spectrum of targets for molecular (neuro) cytognetic studies of neurodevelopmental and neurodegenerative disorders using ICS-MCB. Figure schematically shows these ICS-MCB targets.



Fig. Targets of ICS-MCB in molecular (neuro) cytognetic studies of neurodevelopmental and neurodegenerative disorders (ICS-MCB depiction is from Yurov et al. [26]; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)

The spectrum of ICS-MCB targets evidences for high applicability of this molecular cytogenetic technique for studying brain diseases. Recently, neurodevelopmental and neurodegenerative disorders have been shown to be mediated by a complex pattern of genetic-environmental interactions. It is more probable that chromosomal abnormalities/instability (i.e. aneuploidy and ICB) are important elements of the pathogenetic cascade. In other words, environmental effects interact with specific genomic susceptibility to the instability to cause aneuploidy and ICB [33]. Nuclear chromosome organization might be implicated in pathways to neurodevelopmental and neurodegenerative disorders in a similar way. Therefore, further studies aimed at determination of molecular and cellular pathways to neurodevelopmental and neurodegenerative disorders would benefit from the application of ICS-MCB.

Conclusions. The evaluation of ICS-MCB applicability shows this technique to offer a unique possibility to address chromosomal instability and nuclear chromosome organization in human interphase nuclei. Since the overwhelming majority of human cells are likely to be in interphase, ICS-MCB represents an important tool for chromosomal and genomic research. In summary, complementary surveys of molecular and cellular (genetic and genomic) mechanisms of neurodevelopmental and neurodegenerative disorders are likely to require this interphase cytogenetic approach to chromosomal analysis.

No conflict of interest was recorded with respect to this article.

References

1. Iourov IY, Vorsanova SG, Yurov YB. Molecular cytogenetics and cytogenomics of brain diseases. Curr Genomics. 2008;9(7):452-465. DOI: https://doi.org/10.2174/138920208786241216

2. Parikshak NN, Gandal MJ, Geschwind DH. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet. 2015;16(8):441-458. DOI: https://doi.org/10.1038/nrg3934

3. Yurov YB, Vorsanova SG, Iourov IY. Human Molecular Neurocytogenetics. Curr Genet Med Rep. 2018;6(4):155-164. DOI: https://doi.org/10.1007/s40142-018-0152-y

4. Willsey AJ, Morris MT, Wang S, et al. The psychiatric cell map initiative: a convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. Cell. 2018;174(3):505-520. DOI: https://doi.org/10.1016/j.cell.2018.06.016

5. Youssoufian H, Pyeritz RE. Human genetics and disease: Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3(10):748-758. DOI: https://doi.org/10.1038/nrg906

6. Rohrback S, Siddoway B, Liu CS, et al. Genomic mosaicism in the developing and adult brain. DevNeurobiol. 2018;78(11):1026-1048. DOI: https://doi.org/10.1002/dneu.22626

7. Iourov IY, Vorsanova SG, Yurov YB, et al. Ontogenetic and pathogenetic views on somatic chromosomal mosaicism. Genes (Basel). 2019;10(5). pii: E379. DOI: https://doi.org/10.3390/genes10050379

8. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005;6(10):782-792. DOI: https://doi.org/10.1038/nrg1692

9. Bakker B, van den Bos H, Lansdorp PM, et al. How to count chromosomes in a cell: An overview of current and novel technologies. BioEssays, 2015;37(5):570-577. DOI: https://doi.org/10.1002/bies.201400218

10. Vorsanova SG, Yurov YB, Iourov IY. Human interphase chromosomes: a review of available molecular cytogenetic technologies. MolCytogenet. 2010;3:1. DOI: https://doi.org/10.1186/1755-8166-3-1.

11. Levsky JM, Singer RH. Fluorescence in situ hybridization: past, present and future. J Cell Sci, 2003;116(Pt14):2833-2838. DOI: https://doi.org/10.1242/jcs.00633

12. Yurov YB, Vorsanova SG, Iourov IY, et al. Unexplained autism is frequently associated with low-level mosaic aneuploidy. J Med Genet. 2007;44(8):521-525. DOI: https://doi.org/ https://jmg.bmj.com/content/44/8/521

13. Ferguson-Smith MA. History and evolution of cytogenetics. MolCytogenet. 2015;8:19. DOI: https://doi.org/10.1186/s13039-015-0125-8

14. Cheng L, Zhang S, Wang L, et al. Fluorescence in situ hybridization in surgical pathology: principles and applications. J PatholClin Res. 2017;3(2):73-99. DOI: https://doi.org/10.1002/cjp2.64

15.Ratan ZA, Zaman SB, Mehta V, et al. Application of fluorescence in situ hybridization (FISH) technique for the detection of genetic aberration in medical science. Cureus. 2017;9(6):e1325. DOI: https://doi.org/10.7759/cureus.1325

16.Iourov IY, Liehr T, Vorsanova SG, et al. Visualization of interphase chromosomes in postmitotic cells of the human brain by multicolour banding (MCB). Chromosome Res. 2006;14(3):223-229. DOI: https://doi.org/10.1007/s10577-006-1037-6

17.Iourov IY, Liehr T, Vorsanova SG, et al. Interphase chromosome-specific multicolor banding (ICS-MCB): a new tool for analysis of interphase chromosomes in their integrity. Biomol Eng. 2007;24(4):415-417. DOI: https://doi.org/10.1016/j.bioeng.2007.05.003

18.Riegel M. Human molecular cytogenetics: from cells to nucleotides. Genet Mol Biol. 2014;37(Suppl1):194-209.

19.Arendt T, Mosch B, Morawski M. Neuronal aneuploidy in health and disease: a cytomic approach to understand the molecular individuality of neurons. Int J Mol Sci. 2009;10(4):1609-1627. DOI: https://doi.org/10.3390/ijms10041609

20.Hochstenbach R, Buizer-Voskamp JE, Vorstman JA, et al. Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research. Cytogenet Genome Res. 2011;135(3-4):174-202. DOI: https://doi.org/10.1159/000332928

21.Yurov YB, Vorsanova SG, Solov'ev IV, et al. Instability of chromosomes in human nerve cells (normal and with neuromental diseases). Russ. J. Genet. 2010;46(10):1194-1196. DOI: https://doi.org/10.1134/S1022795410100121

22.Iourov IY, Vorsanova SG, Liehr T, et al. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet. 2009;18(14):2656-69. DOI: https://doi.org/10.1093/hmg/ddp207

23.Leija-Salazar M, Piette C, Proukakis C. Review: Somatic mutations in neurodegeneration. NeuropatholApplNeurobiol. 2018;44(3):267-285. DOI: https://doi.org/10.1111/nan.12465

24.Iourov IY, Vorsanova SG, Liehr T, et al. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol Dis. 2009;34(2):212-220. DOI: https://doi.org/10.1016/j.nbd.2009.01.003

25.Iourov IY, Vorsanova SG, Yurov YB. Genomic landscape of the Alzheimer's disease brain: chromosome instability – aneuploidy, but not tetraploidy – mediates neurodegeneration. Neurodegener Dis. 2011;8(1-2):35-37. DOI: https://doi.org/10.1159/000315398

26.Yurov YB, Vorsanova SG, Liehr T, et al. X chromosome aneuploidy in the Alzheimer's disease brain. MolCytogenet. 2014;7(1):20. DOI: https://doi.org/10.1186/1755-8166-7-20

27.Nudelman KNH, McDonald BC, Lahiri DK, et al. Biological Hallmarks of Cancer in Alzheimer's Disease. MolNeurobiol. 2019:15. DOI: https://doi.org/10.1007/s12035-019-1591-5

28.Yurov YB, Vorsanova SG, Iourov IY. Ontogenetic variation of the human genome. Curr Genomics. 2010;11(6):420-425. DOI: https://doi.org/ 10.2174/138920210793175958

29.Zhang L, Vijg J. Somatic mutagenesis in mammals and its implications for human disease and aging. Annu Rev Genet. 2018;52:397-419. DOI: https://doi.org/10.1146/annurev-genet-120417-031501

30.Iourov I, Vorsanova S, Liehr T, et al. Chromothripsis as a mechanism driving genomic instability mediating brain diseases. MolCytogenet. 2017;10(Suppl 1):20.

31.Horne SD, Chowdhury SK, Heng HH. Stress, genomic adaptation, and the evolutionary trade-off. Front. Genet. 2014;5:92. DOI: https://doi.org/10.3389/fgene.2014.00092

32.Hou Y, Song H, Croteau DL, et al. Genome instability in Alzheimer disease. Mech Ageing Dev. 2017;161(PtA):83-94. DOI: https://doi.org/10.1016/j.mad.2016.04.005

33.Iourov IY, Vorsanova SG, Yurov YB. Somatic cell genomics of brain disorders: a new opportunity to clarify genetic-environmental interactions. Cytogenet Genome Res. 2013;139(3):181-188. DOI: https://doi.org/10.1159/000347053

Information about the authors

Ivan Y. Iourov, Doctor of Biological Sciences, Professor of the Russian Academy of Sciences, Head of Laboratory, Mental Health Research Center, Academician Y.E. Veltishchev Research Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Russian Medical Academy of Continuous Postgraduate Education, E-mail: ivan.iourov@gmail.com, ORCID: 0000-0002-4134-8367.

Thomas Liehr, PhD, PD, Head of Lab, Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany, E-mail: Thomas.Liehr@med.uni-jena.de, ORCID: 0000- 0003-1672-3054.
Svetlana G. Vorsanova, Doctor of Biological Sciences, Professor, Honored Scientist of Russia, Academician of the Russian Academy of Natural Sciences, Head of Laboratory, Academician Y.E. Veltishchev Research Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Mental Health Research Center, E-mail: svorsanova@mail.ru, ORCID: 0000-0002- 4869-5361.
Luis Alberto Mendez-Rosado, PhD, Professor of Havana University of Medicine. Researcher Centro NacionalGenéticaMedica. Havana, E-mail: infomed.sld.cu, ORCID: 0000-0002-4401-0054.
Yuri B. Yurov, Doctor of Biological Sciences, Professor, Honored Scientist of Russia, Academician of the Russian Academy of Natural Sciences, Head of Laboratory, Mental Health Research Center, Academician Y.E. Veltishchev Research Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, ORCID: 0000-0002-9251-2286.

Статья поступила в редакцию 10 июля 2019 г.
Receipt date 2019 July 10.

Статья принята к публикации 15 августа 2019 г.
Accepted for publication 2019 August 15.